Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 2:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 919 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 and Cancer Consortium Registry

NCT04354701
Conditions
COVID-19, Invasive Malignancy (Any Type)
Interventions
Web-based REDCap survey
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19,275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
inodiftagene vixteplasmid
Drug
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more
Conditions
Neurofibromatosis 1
Interventions
Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser, 755nm Alexandrite Laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bladder Cancer, Urinary Cancer, Nonmuscle Invasive Bladder Cancer
Interventions
specimen samples, questionnaires
Genetic · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Invasive Breast Cancer
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
4,385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Interventions
BCG Solution, Cystoscopy, Docetaxel, Gemcitabine, Home Health Encounter, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Bladder Cancer, Urinary Bladder
Interventions
Sunitinib, Gemcitabine, cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Tooth Erosion in People With Esophagogastric Cancer

NCT05612048
Conditions
Esophagogastric Cancer
Interventions
Survey, Intra-oral camera, Optional Salvia sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
Interventions
Cisplatin, Gemcitabine, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Sacituzumab Govitecan
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
296
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 210 more
Conditions
Breast Cancer
Interventions
Lumpectomy without sentinel node biopsy
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Conditions
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive, NRAS wt Allele, NTRK1 Fusion Positive, NTRK2 Fusion Positive, NTRK3 Fusion Positive, RET Fusion Positive, ROS1 Fusion Positive, Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Interventions
Capmatinib, Ceritinib, Entrectinib, Laboratory Biomarker Analysis, Regorafenib
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Conditions
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab
Drug
Lead sponsor
Filipa Lynce, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Active, not recruiting Phase 1Phase 2 Interventional Results available

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

NCT03366844
Conditions
Breast Cancer
Interventions
Pembrolizumab, RT Boost
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2039
U.S. locations
72
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more
Conditions
Breast Cancer
Interventions
Intraductal arm, Intravenous arm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Conditions
Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
Interventions
NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Drug · Other
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more
Conditions
Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Radiation Therapy
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
Cabazitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
Guarionex J. Decastro
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
raloxifene, evaluation of cancer risk factors
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
23 Years to 47 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Conditions
DCIS, Invasive Breast Cancer
Interventions
Stool sample, Skin Swab Sample
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio